An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent ß-thalassemia

计划入组 90 人

TDT 067 Onychomycosis Study

计划入组 738 人 · 首次发布于 2010 年 6 月 17 日

Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

计划入组 654 人 · 首次发布于 2018 年 8 月 29 日

TDT-077

TDT-044

anti-TdT/HLA-A*0201 CAR T-cell therapy (B-ALL/T-ALL)

IDT Biologika GmbH

Germany

IDT Australia Ltd

Atlas Tat Inc.

Canada

YolTech Therapeutics Launches Clinical Trial for In Vivo Gene Editing Therapy YOLT-204 in Transfusion-Dependent Beta-Thalassemia

FDA Approves Casgevy for Beta Thalassemia, Marking Second Indication for First CRISPR-Based Therapy

Vertex Secures Italian Reimbursement for CRISPR Gene Therapy Casgevy, Expanding European Access for Blood Disorders